RESUMO
PURPOSE: Assessment of inflammatory bowel disease (IBD) currently relies on aspecific clinical signs of bowel inflammation. Specific imaging of the diseased bowel regions is still lacking. Here, we investigate mucosal addressin cell adhesion molecule 1 (MAdCAM-1) as a reliable and specific endothelial target for engineered nanoparticles delivering imaging agents to obtain an exact mapping of diseased bowel foci. MATERIALS AND METHODS: We generated a nanodevice composed of PLGA-PEG coupled with anti-MAdCAM-1 antibody half-chains and loaded with quantum dots (P@QD-MdC NPs). Bowel localization and systemic biodistribution of the nanoconjugate were analyzed upon injection in a murine model of chronic IBD obtained through repeated administration of dextran sulfate sodium salt. Specificity for diseased bowel regions was also assessed ex vivo in human specimens from patients with IBD. Potential for development as contrast agent in magnetic resonance imaging was assessed by preliminary study on animal model. RESULTS: Synthesized nanoparticles revealed good stability and monodispersity. Molecular targeting properties were analyzed in vitro in a cell culture model. Upon intravenous injection, P@QD-MdC NPs were localized in the bowel of colitic mice, with enhanced accumulation at 24 h post-injection compared to untargeted nanoparticles (p<0.05). Nanoparticles injection did not induce histologic lesions in non-target organs. Ex vivo exposure of human bowel specimens to P@QD-MdC NPs revealed specific recognition of the diseased regions vs uninvolved tracts (p<0.0001). After loading with appropriate contrast agent, the nanoparticles enabled localized contrast enhancement of bowel mucosa in the rectum of treated mice. CONCLUSION: P@QD-MdC NPs efficiently detected bowel inflammation foci, accurately following the expression pattern of MAdCAM-1. Fine-tuning of this nanoconjugate with appropriate imaging agents offers a promising non-invasive tool for specific IBD diagnosis.
Assuntos
Moléculas de Adesão Celular/imunologia , Imunoconjugados/administração & dosagem , Doenças Inflamatórias Intestinais/diagnóstico por imagem , Mucoproteínas/imunologia , Pontos Quânticos/administração & dosagem , Animais , Anticorpos Monoclonais/química , Anticorpos Monoclonais/imunologia , Colite/induzido quimicamente , Colite/diagnóstico por imagem , Doença de Crohn/diagnóstico por imagem , Modelos Animais de Doenças , Feminino , Humanos , Imunoconjugados/farmacocinética , Injeções Intravenosas , Mucosa Intestinal/diagnóstico por imagem , Intestinos/diagnóstico por imagem , Imageamento por Ressonância Magnética/métodos , Camundongos Endogâmicos C57BL , Nanopartículas/administração & dosagem , Nanopartículas/química , Poliésteres/química , Polietilenoglicóis/química , Distribuição TecidualRESUMO
Notwithstanding the positive clinical impact of endocrine therapies in estrogen receptor-alpha (ERα)-positive breast cancer, de novo and acquired resistance limits the therapeutic lifespan of existing drugs. Taking the position that resistance is nearly inevitable, we undertook a study to identify and exploit targetable vulnerabilities that were manifest in endocrine therapy-resistant disease. Using cellular and mouse models of endocrine therapy-sensitive and endocrine therapy-resistant breast cancer, together with contemporary discovery platforms, we identified a targetable pathway that is composed of the transcription factors FOXA1 and GRHL2, a coregulated target gene, the membrane receptor LYPD3, and the LYPD3 ligand, AGR2. Inhibition of the activity of this pathway using blocking antibodies directed against LYPD3 or AGR2 inhibits the growth of endocrine therapy-resistant tumors in mice, providing the rationale for near-term clinical development of humanized antibodies directed against these proteins.
Assuntos
Fator 3-alfa Nuclear de Hepatócito/metabolismo , Neoplasias Mamárias Experimentais/metabolismo , Fatores de Transcrição/metabolismo , Animais , Anticorpos Neutralizantes/imunologia , Anticorpos Neutralizantes/uso terapêutico , Moléculas de Adesão Celular/imunologia , Moléculas de Adesão Celular/metabolismo , Resistencia a Medicamentos Antineoplásicos , Receptor alfa de Estrogênio/genética , Feminino , Proteínas Ligadas por GPI/imunologia , Proteínas Ligadas por GPI/metabolismo , Humanos , Células MCF-7 , Neoplasias Mamárias Experimentais/tratamento farmacológico , Neoplasias Mamárias Experimentais/genética , Camundongos , Mucoproteínas/imunologia , Mucoproteínas/metabolismo , Proteínas Oncogênicas/imunologia , Proteínas Oncogênicas/metabolismoRESUMO
INTRODUCTION: Mucosal addressin cell adhesion molecule-1 (MAdCAM-1) expression in gut-associated lymphoid tissue is upregulated in patients with inflammatory bowel disease (IBD). Blocking adhesion molecules and thereby inhibiting migration of lymphocytes into sites of inflammation in the gut is an attractive new treatment target in drug development for IBD. AREAS COVERED: This review discusses the preclinical and clinical experience on SHP647 (previously called PF-00547659 and PF-00547,659), a fully human IgG2K monoclonal antibody that binds to MAdCAM-1 to selectively reduce lymphocyte homing to the intestinal tract. EXPERT OPINION: Blocking endothelial adhesion molecule MAdCAM-1 could represent an attractive target for the treatment of IBD. In the next years, the results from the phase III studies as well as data to support therapeutic drug monitoring based on drug levels to guide and optimize individual therapy will become available. Furthermore, much effort is put in the development of clinical prediction models to predict which drug is optimal for an individual patient.
Assuntos
Anticorpos Monoclonais Humanizados/uso terapêutico , Moléculas de Adesão Celular/imunologia , Doenças Inflamatórias Intestinais/tratamento farmacológico , Mucoproteínas/imunologia , Animais , Anticorpos Monoclonais Humanizados/efeitos adversos , Ensaios Clínicos como Assunto , Colite Ulcerativa/tratamento farmacológico , Colite Ulcerativa/patologia , Doença de Crohn/tratamento farmacológico , Doença de Crohn/patologia , Avaliação Pré-Clínica de Medicamentos , Humanos , Doenças Inflamatórias Intestinais/patologiaRESUMO
OBJECTIVE: To define pharmacodynamic biomarkers in the peripheral blood of patients with Crohn's disease [CD] after treatment with PF-00547659, an anti-human mucosal addressin cell adhesion molecule-1 [MAdCAM-1] monoclonal antibody. METHODS: In this Phase 2, randomised, double-blind, controlled study [OPERA], blood samples were analysed from patients with moderate to severe active CD who received placebo or 22.5 mg, 75 mg, or 225 mg of PF-00547659 subcutaneously at baseline and at Weeks 4 and 8, with follow-up at Week 12. Soluble MAdCAM [sMAdCAM] was measured by mass spectrometry, ß7-expressing T cells by flow cytometry, and gene transcriptome by RNA sequencing. RESULTS: A slight increase in sMAdCAM was measured in the placebo group from baseline to Week 12 [6%], compared with significant decreases in all PF-00547659 groups [-87% to -98%]. A slight increase from baseline to Week 12 was observed in frequency and molecules of equivalent soluble fluorochrome for ß7+ central memory T cells in the placebo group [4%], versus statistically significant increases in the active treatment groups [48% to 81%]. Similar trends were seen for ß7+ effector memory T cells [placebo, 8%; PF-00547659, 84-138%] and ß7+ naïve T cells [8%; 13-50%]. CCR9 gene expression had statistically significant up-regulation [p = 1.09e-06; false discovery rate < 0.1] with PF-00547659 treatment, and was associated with an increase in ß7+ T cells. CONCLUSIONS: Results of the OPERA study demonstrate positive pharmacology and dose-dependent changes in pharmacodynamic biomarker measurements in blood, including changes in cellular composition of lymphocytes and corresponding CCR9 gene expression changes.
Assuntos
Anticorpos Monoclonais Humanizados/farmacologia , Doença de Crohn/sangue , Imunoglobulinas/sangue , Mucoproteínas/sangue , Receptores CCR/genética , Linfócitos T , Transcriptoma/efeitos dos fármacos , Adulto , Anticorpos Monoclonais Humanizados/uso terapêutico , Biomarcadores/sangue , Proteína C-Reativa/metabolismo , Moléculas de Adesão Celular , Doença de Crohn/tratamento farmacológico , Método Duplo-Cego , Fezes/química , Feminino , Humanos , Imunoglobulinas/imunologia , Cadeias beta de Integrinas/metabolismo , Complexo Antígeno L1 Leucocitário/análise , Contagem de Linfócitos , Masculino , Pessoa de Meia-Idade , Mucoproteínas/imunologia , Índice de Gravidade de Doença , Linfócitos T/metabolismo , Regulação para Cima/efeitos dos fármacos , Adulto JovemRESUMO
BACKGROUND: The precise mechanisms controlling homing of T effector (Teff) cells to the inflamed gut in Crohn's disease (CD) are still unclear, and clinical outcome data from patients with inflammatory bowel disease treated with the anti-α4ß7 integrin antibody vedolizumab suggest differences between ulcerative colitis and CD. METHODS: Expression of homing molecules was studied with flow cytometry and immunohistochemistry. Their functional role was investigated in in vitro adhesion assays and in a humanized mouse model of T cell homing to the inflamed gut in vivo. RESULTS: Despite in vitro blockade of CD Teff adhesion to mucosal vascular addressin cell adhesion molecule-1 (MadCAM-1) and in contrast to previous observations in ulcerative colitis, anti-α4ß7 treatment did not result in reduced Teff cell homing to the colon in vivo. However, the integrin α4ß1 was expressed in higher levels on Teffs from patients with CD compared with controls, while its expression in the peripheral blood declined, and its expression in the intestine increased during the course of clinical vedolizumab treatment. Consistently, adhesion of CD Teffs to vascular cell adhesion molecule-1 (VCAM-1) was blocked by inhibition of α4 and α4ß1 in vitro. Moreover, in vivo homing of CD Teffs to the ileum was reduced by inhibition of α4 and α4ß1 integrins, but not α4ß7 integrins. CONCLUSIONS: Our findings suggest that Teff cell homing to the ileum through the axis α4ß1-VCAM-1 is an essential and nonredundant pathway in CD in vivo, possibly affecting efficacy of clinical treatment with antiadhesion compounds.
Assuntos
Doença de Crohn/imunologia , Íleo/imunologia , Integrina alfa4beta1/imunologia , Receptores de Retorno de Linfócitos/imunologia , Linfócitos T/imunologia , Adulto , Animais , Anticorpos Monoclonais Humanizados/farmacologia , Moléculas de Adesão Celular , Movimento Celular , Colite Ulcerativa/tratamento farmacológico , Colite Ulcerativa/imunologia , Colite Ulcerativa/patologia , Doença de Crohn/tratamento farmacológico , Doença de Crohn/patologia , Feminino , Citometria de Fluxo , Fármacos Gastrointestinais/farmacologia , Humanos , Íleo/patologia , Imunoglobulinas/efeitos dos fármacos , Imunoglobulinas/imunologia , Imuno-Histoquímica , Integrina alfa4beta1/efeitos dos fármacos , Masculino , Camundongos , Mucoproteínas/efeitos dos fármacos , Mucoproteínas/imunologia , Receptores de Retorno de Linfócitos/efeitos dos fármacos , Linfócitos T/efeitos dos fármacos , Molécula 1 de Adesão de Célula Vascular/efeitos dos fármacos , Molécula 1 de Adesão de Célula Vascular/imunologiaRESUMO
BACKGROUND: The current study was designed to determine the effects of antibody blockade of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) on the proinflammatory activity of mesenteric lymph after hemorrhagic shock and resuscitation (HS/R). METHODS: Rats were subjected to HS/R with or without treatment with MAdCAM-1 polyclonal antibody. MAdCAM-1 expression and lymphocyte infiltration in rats were examined. Post-shock mesenteric lymph was collected, filtered to remove lymphocytes, and transfused into recipient mice to induce systemic inflammation and intestinal injury. The proinflammatory activity of post-shock lymph in mice was determined by examining intestinal permeability, enterocyte apoptosis, intestinal lactate levels, lung myeloperoxidase (MPO) activity, and serum cytokine levels. Survival of recipient mice was determined over a 1-week time period. RESULTS: Rats subjected to HS/R had increased MAdCAM-1 expression and lymphocyte infiltration in the intestine. Antibody blockade of MAdCAM-1 attenuated the increased lymphocyte infiltration after HS/R (P < .05). Post-shock mesenteric lymph transfusion significantly increased mortality accompanied by increases in gut permeability, enterocyte apoptosis, intestinal lactate levels, lung MPO activity, and serum levels of interleukin (IL)-1ß, IL-6, tumor necrosis factor (TNF)-α, IL-10, and transforming growth factor-ß (all P < .05). Antibody blockade of MAdCAM-1 in rats subjected to HS/R attenuated the proinflammatory activity of post-shock mesenteric lymph, with abrogation of lymph transfusion-induced increases in mortality, gut permeability, epithelial cell apoptosis, intestinal lactate levels, lung MPO activity, and serum levels of IL-1ß, IL-6, and TNF-α (all P < .05). CONCLUSION: These findings demonstrate that antibody blockade of MAdCAM-1 attenuates the proinflammatory activity of mesenteric lymph after HS/R.
Assuntos
Autoanticorpos/uso terapêutico , Imunoglobulinas/imunologia , Fatores Imunológicos/uso terapêutico , Intestinos/imunologia , Linfa/imunologia , Mesentério/imunologia , Mucoproteínas/imunologia , Choque Hemorrágico/tratamento farmacológico , Animais , Terapia Combinada , Imunoglobulinas/metabolismo , Intestinos/fisiopatologia , Ativação Linfocitária , Masculino , Mucoproteínas/metabolismo , Distribuição Aleatória , Ratos , Ratos Sprague-Dawley , Ressuscitação , Choque Hemorrágico/imunologia , Choque Hemorrágico/fisiopatologia , Choque Hemorrágico/terapia , Resultado do TratamentoRESUMO
BACKGROUND: Vedolizumab is a monoclonal antibody approved for use in ulcerative colitis and Crohn's disease. By specifically binding to α4 ß7 integrin, vedolizumab prevents trafficking of lymphocytes to the gut, thereby interfering with disease pathology. During the clinical development program, the pharmacodynamic effect of vedolizumab was evaluated by 2 flow cytometry receptor occupancy assays: act-1 (ACT-1) and mucosal addressin cell adhesion molecule-1 (MAdCAM-1). Here we describe the development and validation of these assays. METHODS: The ACT-1 assay is a receptor occupancy free-site assay that uses a monoclonal antibody with the same binding epitope as vedolizumab to detect free (unbound) sites on α4 ß7 integrin. The MAdCAM-1 assay used a soluble version of the natural ligand for α4 ß7 integrin to detect free sites. The assays were validated using a fit-for-purpose approach throughout the clinical development of vedolizumab. RESULTS: Both the ACT-1 assay and the MAdCAM-1 assay demonstrated acceptable reproducibility and repeatability. The assays were sufficiently stable to allow for clinical use. During clinical testing the assays demonstrated that vedolizumab was able to saturate peripheral cells at all doses tested. CONCLUSIONS: Two pharmacodynamic receptor occupancy assays were developed and validated to assess the effect of vedolizumab on peripheral blood cells. The results of these assays demonstrated the practical use of flow cytometry to examine pharmacodynamic response in clinical trials.
Assuntos
Colite Ulcerativa/tratamento farmacológico , Citometria de Fluxo , Imunoglobulinas/isolamento & purificação , Mucoproteínas/isolamento & purificação , Peptídeos e Proteínas Associados a Receptores de Fatores de Necrose Tumoral/isolamento & purificação , Proteínas Adaptadoras de Transdução de Sinal , Anticorpos Monoclonais/administração & dosagem , Anticorpos Monoclonais/imunologia , Anticorpos Monoclonais Humanizados/administração & dosagem , Anticorpos Monoclonais Humanizados/imunologia , Biomarcadores/sangue , Adesão Celular/imunologia , Moléculas de Adesão Celular , Colite Ulcerativa/sangue , Colite Ulcerativa/imunologia , Humanos , Imunoglobulinas/sangue , Imunoglobulinas/imunologia , Integrinas/imunologia , Integrinas/metabolismo , Linfócitos/imunologia , Mucoproteínas/sangue , Mucoproteínas/imunologia , Pacientes , Peptídeos e Proteínas Associados a Receptores de Fatores de Necrose Tumoral/sangue , Peptídeos e Proteínas Associados a Receptores de Fatores de Necrose Tumoral/imunologiaRESUMO
The adoptive transfer of CD4+CD25+Foxp3+ regulatory T cells (Tregs) in murine models of allogeneic hematopoietic cell transplantation (HCT) has been shown to protect recipient mice from lethal acute graft-versus-host disease (GVHD) and this approach is being actively investigated in human clinical trials. Here, we examined the effects of cryopreservation on Tregs. We found that freeze and thaw of murine and human Tregs is associated with reduced expression of L-selectin (CD62L), which was previously established to be an important factor that contributes to the in vivo protective effects of Tregs. Frozen and thawed murine Tregs showed a reduced capacity to bind to the CD62L binding partner MADCAM1 in vitro as well as an impaired homing to secondary lymphoid organs in vivo. Upon adoptive transfer frozen and thawed Tregs failed to protect against lethal GVHD compared with fresh Tregs in a murine model of allogeneic HCT across major histocompatibility barriers. In summary, the direct administration of adoptively transferred frozen and thawed Tregs adversely affects their immunosuppressive potential which is an important factor to consider in the clinical implementation of Treg immunotherapies.
Assuntos
Criopreservação , Regulação da Expressão Gênica/imunologia , Doença Enxerto-Hospedeiro/imunologia , Transplante de Células-Tronco Hematopoéticas , Selectina L/imunologia , Linfócitos T Reguladores/imunologia , Transferência Adotiva , Aloenxertos , Animais , Moléculas de Adesão Celular/imunologia , Modelos Animais de Doenças , Doença Enxerto-Hospedeiro/patologia , Doença Enxerto-Hospedeiro/prevenção & controle , Humanos , Imunoglobulinas/genética , Imunoglobulinas/imunologia , Camundongos , Camundongos Endogâmicos BALB C , Mucoproteínas/genética , Mucoproteínas/imunologia , Linfócitos T Reguladores/patologia , Linfócitos T Reguladores/transplanteRESUMO
Here we determined whether immunostimulatory plant-derived arabinogalactan proteins (AGPs) and the honeybee-derived protein apisimin are present in varieties of New Zealand honey. Apisimin is a protein of unknown function secreted from the glands of honeybees into Royal Jelly, forming a complex with apalbumin1 capable of stimulating lymphocyte proliferation. AGPs were abundant in kanuka honey with lesser amounts in manuka, kowhai and clover honeys, but absent from Royal Jelly. Apisimin was present in all honeys, as well as Royal Jelly. We report that apisimin shares with honey AGPs the ability to stimulate the release of TNF-α from blood monocytes. Further, it synergizes with AGPs to enhance the release of TNF-α, via a mechanism not involving the formation of a complex with AGPs. In summary, this study provides evidence that AGPs and apisimin are commonly present in different floral varieties of honey, and hence contribute to their immunostimulatory properties.
Assuntos
Mel/análise , Proteínas de Insetos/análise , Monócitos/imunologia , Mucoproteínas/análise , Animais , Abelhas , Células Cultivadas , Ácidos Graxos/análise , Ácidos Graxos/imunologia , Humanos , Proteínas de Insetos/imunologia , Proteínas de Insetos/farmacologia , Monócitos/efeitos dos fármacos , Mucoproteínas/imunologia , Nova Zelândia , Proteínas de Plantas/análise , Proteínas de Plantas/imunologia , Fator de Necrose Tumoral alfa/imunologiaRESUMO
The human hCLCA1 and its murine ortholog mCLCA3 (calcium-activated chloride channel regulators) are exclusively expressed in mucus cells and linked to inflammatory airway diseases with increased mucus production, such as asthma, cystic fibrosis and chronic obstructive pulmonary disease. Both proteins have a known impact on the mucus cell metaplasia trait in these diseases. However, growing evidence points towards an additional role in innate immune responses. In the current study, we analyzed Staphylococcus aureus pneumonia, an established model to study pulmonary innate immunity, in mCLCA3-deficient and wild-type mice, focusing on the cellular and cytokine-driven innate inflammatory response. We compared clinical signs, bacterial clearance, leukocyte immigration and cytokine responses in the bronchoalveolar compartment, as well as pulmonary vascular permeability, histopathology, mucus cell number and mRNA expression levels of selected genes (mClca1 to 7, Muc5ac, Muc5b, Muc2, Cxcl-1, Cxcl-2, Il-17). Deficiency of mCLCA3 resulted in decreased neutrophilic infiltration into the bronchoalveolar space during bacterial infection. Only the cytokines IL-17 and the murine CXCL-8 homolog CXCL-1 were decreased on mRNA and protein levels during bacterial infection in mCLCA3-deficient mice compared to wild-type controls. However, no differences in clinical outcome, histopathology or mucus cell metaplasia were observed. We did not find evidence for regulation of any other CLCA homolog that would putatively compensate for the lack of mCLCA3. In conclusion, mCLCA3 appears to modulate leukocyte response via IL-17 and murine CXCL-8 homologs in acute Staphylococcus aureus pneumonia which is well in line with the proposed function of hCLCA1 as a signaling molecule acting on alveolar macrophages.
Assuntos
Quimiocina CXCL1/biossíntese , Canais de Cloreto/imunologia , Interleucina-17/biossíntese , Mucoproteínas/imunologia , Pneumonia Estafilocócica/imunologia , Staphylococcus aureus/imunologia , Animais , Líquido da Lavagem Broncoalveolar/citologia , Líquido da Lavagem Broncoalveolar/imunologia , Permeabilidade Capilar/imunologia , Movimento Celular/imunologia , Quimiocina CXCL1/imunologia , Canais de Cloreto/genética , Citocinas/imunologia , Citocinas/metabolismo , Modelos Animais de Doenças , Feminino , Imunidade Inata/imunologia , Inflamação , Interleucina-17/imunologia , Leucócitos/imunologia , Pulmão/imunologia , Pulmão/microbiologia , Pulmão/patologia , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Mucinas/biossíntese , Mucoproteínas/genética , Infiltração de Neutrófilos/imunologia , Neutrófilos/imunologia , Pneumonia Estafilocócica/microbiologia , RNA Mensageiro/biossíntese , Distribuição Aleatória , Infecções Estafilocócicas/imunologia , Infecções Estafilocócicas/microbiologia , Staphylococcus aureus/crescimento & desenvolvimentoRESUMO
IL-27 is a heterodimeric cytokine composed of the subunits p28 and Epstein-Barr virus induced gene (EBI)-3 and is known for its effects on T-cell function and differentiation. IL-27 signals through the widely expressed IL-27 receptor (IL-27R), composed of the ligand-specific IL-27Rα chain and gp130. Engagement of the IL-27R activates STAT1 signaling, induces the expression of the type 1 helper T-cell (Th1) cytokine, interferon γ, and suppresses the differentiation of Th2 and Th17 cells. This study investigates the role of IL-27 signaling in respiratory syncytial virus (RSV) infection using IL-27Rα-deficient mice (IL-27rKO). Analysis of lungs from RSV-infected IL-27rKO mice showed exacerbation of mucus secretion compared with wild type, as well as enhanced expression of Muc5ac and Gob5 mRNA, markers of goblet cell metaplasia/hyperplasia. When compared with wild-type mice, RSV-challenged IL-27rKO mice had enhanced expression of Th17-associated cytokine IL-17a and an imbalance between Th1 and Th2 cytokine levels. Neutralization of IL-17 in RSV-infected IL-27rKO mice resulted in a significant decrease in the pulmonary mucus response and inhibition of the Th2-associated cytokines. Interestingly, IL-17 blockage led to an increase in the expression of IL-27 subunits p28 and EBI-3 in the lungs and lymph nodes of RSV-infected mice. Thus, IL-27 functions as a regulatory cytokine during RSV pathogenesis by suppressing the development of Th17 cells, but it also appears to be regulated by IL-17 induced by the virus.
Assuntos
Interleucina-17/imunologia , Receptores de Citocinas/imunologia , Infecções por Vírus Respiratório Sincicial/imunologia , Vírus Sinciciais Respiratórios/imunologia , Células Th17/imunologia , Células Th2/imunologia , Animais , Canais de Cloreto/genética , Canais de Cloreto/imunologia , Interleucina-17/genética , Interleucinas/genética , Interleucinas/imunologia , Camundongos , Camundongos Knockout , Antígenos de Histocompatibilidade Menor , Mucina-5AC/genética , Mucina-5AC/imunologia , Mucoproteínas/genética , Mucoproteínas/imunologia , Muco/imunologia , Receptores de Citocinas/genética , Receptores de Interleucina , Infecções por Vírus Respiratório Sincicial/genética , Infecções por Vírus Respiratório Sincicial/patologia , Fator de Transcrição STAT1/genética , Fator de Transcrição STAT1/imunologia , Células Th17/patologia , Células Th2/patologiaRESUMO
BACKGROUND: Asthma is a complex and heterogeneous chronic inflammatory disorder that is associated with mucous cell metaplasia and mucus hypersecretion. Functional genomic analysis indicates that mucous cell metaplasia and mucus hypersecretion depend on members of the calcium-activated chloride channel (CLCA) gene family. It has been reported that the inhibition of CLCAs could relieve the symptoms of asthma. Thus, the mCLCA3 antibody may be a promising strategy to treat allergic diseases such as asthma. METHODS: We constructed asthmatic mouse models of OVA-induced chronic airway inflammatory disorder to study the function of the mCLCA3 antibody. Airway inflammation was measured by HE staining; goblet cell hyperplasia and mucus hypersecretion were detected by PAS staining; muc5ac, IL-13, IFN-γ levels in bronchoalveolar lavage fluid (BALF) were examined by ELISA; Goblet cell apoptosis was measured by TUNEL assay and alcian blue staining; mCLCA3, Bcl-2 and Bax expression were detected by RT-PCR, Western blotting and immunohistochemical analysis. RESULTS: In our study, mice treated with mCLCA3 antibody developed fewer pathological changes compared with control mice and asthmatic mice, including a remarkable reduction in airway inflammation, the number of goblet cells and mCLCA3 expression in lung tissue. The levels of muc5ac and IL-13 were significantly reduced in BALF. We also found that the rate of goblet cell apoptosis was increased after treatment with mCLCA3 antibody, which was accompanied by an increase in Bax levels and a decrease in Bcl-2 expression in goblet cells. CONCLUSIONS: Taken together, our results indicate that mCLCA3 antibody may have the potential as an effective pharmacotherapy for asthma.
Assuntos
Anticorpos/uso terapêutico , Asma/tratamento farmacológico , Canais de Cloreto/imunologia , Mucoproteínas/imunologia , Animais , Anticorpos/farmacologia , Apoptose/efeitos dos fármacos , Apoptose/genética , Asma/patologia , Líquido da Lavagem Broncoalveolar , Citocinas/metabolismo , Modelos Animais de Doenças , Feminino , Células Caliciformes/efeitos dos fármacos , Células Caliciformes/patologia , Hiperplasia , Inflamação/patologia , Camundongos , Camundongos Endogâmicos BALB C , Mucina-5AC/metabolismo , Ovalbumina/imunologia , Sistema Respiratório/efeitos dos fármacos , Sistema Respiratório/patologiaRESUMO
Mucins are gel-forming proteins that are responsible for the characteristic viscoelastic properties of mucus. Mucin overproduction is a hallmark of asthma, but the cellular requirements for airway mucin production are poorly understood. The endoplasmic reticulum (ER) protein anterior gradient homolog 2 (AGR2) is required for production of the intestinal mucin MUC2, but its role in the production of the airway mucins MUC5AC and MUC5B is not established. Microarray data were analyzed to examine the relationship between AGR2 and MUC5AC expression in asthma. Immunofluorescence was used to localize AGR2 in airway cells. Coimmunoprecipitation was used to identify AGR2-immature MUC5AC complexes. Agr2(-/-) mice were used to determine the role of AGR2 in allergic airway disease. AGR2 localized to the ER of MUC5AC- and MUC5B-producing airway cells and formed a complex with immature MUC5AC. AGR2 expression increased together with MUC5AC expression in airway epithelium from "Th2-high" asthmatics. Allergen-challenged Agr2(-/-) mice had greater than 50% reductions in MUC5AC and MUC5B proteins compared with allergen-challenged wild-type mice. Impaired mucin production in Agr2(-/-) mice was accompanied by an increase in the proportion of mucins contained within the ER and by evidence of ER stress in airway epithelium. This study shows that AGR2 increases with mucin overproduction in individuals with asthma and in mouse models of allergic airway disease. AGR2 interacts with immature mucin in the ER and loss of AGR2 impairs allergen-induced MUC5AC and MUC5B overproduction.
Assuntos
Alérgenos/administração & dosagem , Asma/metabolismo , Mucina-5AC/biossíntese , Mucina-5B/biossíntese , Mucoproteínas/biossíntese , Proteínas/metabolismo , Alérgenos/imunologia , Animais , Asma/genética , Asma/imunologia , Hiper-Reatividade Brônquica/genética , Hiper-Reatividade Brônquica/imunologia , Hiper-Reatividade Brônquica/metabolismo , Linhagem Celular Tumoral , Retículo Endoplasmático/imunologia , Retículo Endoplasmático/metabolismo , Expressão Gênica , Humanos , Hipersensibilidade Imediata/genética , Hipersensibilidade Imediata/imunologia , Hipersensibilidade Imediata/metabolismo , Inflamação/genética , Inflamação/imunologia , Inflamação/metabolismo , Camundongos , Camundongos Transgênicos , Mucina-5AC/genética , Mucina-5AC/imunologia , Mucina-5AC/metabolismo , Mucina-5B/genética , Mucina-5B/imunologia , Mucina-5B/metabolismo , Mucoproteínas/genética , Mucoproteínas/imunologia , Mucoproteínas/metabolismo , Proteínas Oncogênicas , Proteínas/genética , Proteínas/imunologia , Mucosa Respiratória/imunologia , Mucosa Respiratória/metabolismo , Células Th2/imunologia , Células Th2/metabolismoRESUMO
BACKGROUND AND AIMS: Leucocyte migration to gut mucosa, mediated by integrin binding to mucosal addressin cell adhesion molecule (MAdCAM), is a promising target for therapeutic intervention in inflammatory bowel disease. This first-in-human study of a monoclonal antibody to MAdCAM, PF-00547,659, aimed to explore the safety and preliminary efficacy of this gut-specific mechanism in ulcerative colitis. METHODS: In this randomised, double-blind placebo-controlled study, 80 patients with active ulcerative colitis received single or multiple (three doses, 4-week intervals) doses of PF-00547,659 0.03-10 mg/kg IV/SC, or placebo. Safety was assessed by adverse events, laboratory tests, and immunogenicity. Exploratory efficacy analyses were based on Mayo score and endoscopic responder rates at weeks 4 and 12. Faecal calprotectin was quantified as a measure of disease activity, and the number of α4ß7⺠lymphocytes was measured to demonstrate drug activity. RESULTS: No obvious drug-related side effects were observed in the PF-00547,659 group, while patient numbers, especially those fully exposed, were small. Overall responder/remission rates at 4 and 12 weeks were 52%/13% and 42%/22%, respectively with combined PF-00547,659 doses compared with 32%/11% and 21%/0%, respectively with placebo. Equivalent endoscopic responder rates were 50% and 42% versus 26% and 29%, respectively. Faecal calprotectin levels decreased to a greater extent with PF-00547,659 than placebo (week 4: 63% vs 18%). Despite variability, there was a trend for an increase in α4ß7⺠lymphocytes in patients receiving PF-00547,659. CONCLUSIONS: The favourable short-term safety profile and preliminary efficacy findings for PF-00547,659 in this first-in-human study pave the way for further investigation in larger trials, to establish the role of PF-00547,659 in ulcerative colitis treatment. Trial Register No: NCT00928681.
Assuntos
Anticorpos Monoclonais/uso terapêutico , Colite Ulcerativa/terapia , Imunoglobulinas/imunologia , Mucoproteínas/imunologia , Anticorpos Monoclonais/administração & dosagem , Anticorpos Monoclonais/imunologia , Adesão Celular/imunologia , Moléculas de Adesão Celular , Colite Ulcerativa/imunologia , Colite Ulcerativa/patologia , Colonoscopia , Relação Dose-Resposta a Droga , Método Duplo-Cego , Feminino , Citometria de Fluxo , Seguimentos , Humanos , Imunidade Celular , Imunoglobulinas/metabolismo , Infusões Intravenosas , Linfócitos/imunologia , Linfócitos/patologia , Masculino , Pessoa de Meia-Idade , Mucoproteínas/metabolismo , Indução de Remissão , Estudos Retrospectivos , Resultado do TratamentoRESUMO
BACKGROUND: Pyelonephritis is a serious disease in pig production that needs to be further studied. The purpose of this study was to describe the morphology, investigate the pathogenesis, and evaluate the aetiological role of Escherichia coli in pyelonephritis in slaughtered pigs by concurrent bacteriological, gross and histopathological examinations. METHODS: From Danish abattoirs, kidneys and corresponding lymph nodes from 22 slaughtered finishing pigs and 26 slaughtered sows with pyelonephritis were collected and evaluated by bacteriology and pathology. Based on gross lesions, each kidney (lesion) was grouped as acute, chronic, chronic active, or normal and their histological inflammatory stage was determined as normal (0), acute (1), sub-acute (2), chronic active (3), or chronic (4). Immunohistochemical identification of neutrophils, macrophages, T-lymphocytes, B-lymphocytes, plasma cells, E. coli and Tamm-Horsfall protein (THP) in renal sections was performed. The number of E. coli and the proportion of immunohistochemically visualized leukocytes out of the total number of infiltrating leukocytes were scored semi-quantitatively. RESULTS: Lesions in finishing pigs and sows were similar. Macroscopically, multiple unevenly distributed foci of inflammation mostly affecting the renal poles were observed. Histologically, tubulointerstitial infiltration with neutrophils and mononuclear cells and tubular destruction was the main findings. The significant highest scores of L1 antigen+ neutrophils were in inflammatory stage 1 while the significant highest scores of CD79alphacy+ B-lymphocytes, IgG+ and IgA+ plasma cells were in stage 3 or 4. Neutrophils were the dominant leukocytes in stage 1 while CD3epsilon+ T-lymphocytes dominated in stage 2, 3 and 4. Interstitially THP was seen in 82% and 98% of kidneys with pyelonephritis from finishing pigs and sows, respectively. E. coli was demonstrated in monoculture and/or identified by immunohistochemistry in relation to inflammation in four kidneys from finishing pigs and in 34 kidneys from sows. CONCLUSIONS: E. coli played a significant role in the aetiology of pyelonephritis. Neutrophils were involved in the first line of defence. CD3epsilon+ T-lymphocytes were involved in both the acute and chronic inflammatory response while a humoral immune response was most pronounced in later inflammatory stages. The observed renal lesions correspond with an ascending bacterial infection with presence of intra-renal reflux.
Assuntos
Infecções por Escherichia coli/veterinária , Escherichia coli/imunologia , Pielonefrite/veterinária , Doenças dos Suínos/microbiologia , Animais , Linfócitos B/imunologia , Linfócitos B/patologia , Infecções por Escherichia coli/imunologia , Infecções por Escherichia coli/microbiologia , Infecções por Escherichia coli/patologia , Feminino , Imuno-Histoquímica/veterinária , Macrófagos/imunologia , Macrófagos/patologia , Masculino , Mucoproteínas/imunologia , Neutrófilos/imunologia , Neutrófilos/patologia , Pielonefrite/imunologia , Pielonefrite/microbiologia , Pielonefrite/patologia , Suínos , Doenças dos Suínos/imunologia , Doenças dos Suínos/patologia , Linfócitos T/imunologia , Linfócitos T/patologia , UromodulinaRESUMO
Uromodulin (UMOD) mutations are responsible for three autosomal dominant tubulo-interstitial nephropathies including medullary cystic kidney disease type 2 (MCKD2), familial juvenile hyperuricemic nephropathy and glomerulocystic kidney disease. Symptoms include renal salt wasting, hyperuricemia, gout, hypertension and end-stage renal disease. MCKD is part of the 'nephronophthisis-MCKD complex', a group of cystic kidney diseases. Both disorders have an indistinguishable histology and renal cysts are observed in either. For most genes mutated in cystic kidney disease, their proteins are expressed in the primary cilia/basal body complex. We identified seven novel UMOD mutations and were interested if UMOD protein was expressed in the primary renal cilia of human renal biopsies and if mutant UMOD would show a different expression pattern compared with that seen in control individuals. We demonstrate that UMOD is expressed in the primary cilia of renal tubules, using immunofluorescent studies in human kidney biopsy samples. The number of UMOD-positive primary cilia in UMOD patients is significantly decreased when compared with control samples. Additional immunofluorescence studies confirm ciliary expression of UMOD in cell culture. Ciliary expression of UMOD is also confirmed by electron microscopy. UMOD localization at the mitotic spindle poles and colocalization with other ciliary proteins such as nephrocystin-1 and kinesin family member 3A is demonstrated. Our data add UMOD to the group of proteins expressed in primary cilia, where mutations of the gene lead to cystic kidney disease.
Assuntos
Cílios/metabolismo , Rim/metabolismo , Mucoproteínas/metabolismo , Mutação/genética , Proteínas Adaptadoras de Transdução de Sinal/metabolismo , Adolescente , Adulto , Animais , Anticorpos/imunologia , Biópsia , Western Blotting , Divisão Celular , Células Cultivadas , Criança , Cílios/ultraestrutura , Proteínas do Citoesqueleto , Imunofluorescência , Humanos , Rim/patologia , Rim/ultraestrutura , Cinesinas/metabolismo , Proteínas de Membrana/metabolismo , Camundongos , Pessoa de Meia-Idade , Mucoproteínas/imunologia , Proteínas Mutantes/metabolismo , Transporte Proteico , Transfecção , Uromodulina , Adulto JovemRESUMO
AIM: Human renal tubular cells of well-defined nephron origin are an important basis in the research of various physiological and pathophysiological mechanisms in the kidney. Whereas an exceeding amount of data has been obtained on proximal tubular cells, only limited data of cells of the human thick ascending limb and the early distal tubule (TALDC) are available. METHODS: TALDC have been isolated immunomagnetically according to their specific antigen expression of Tamm-Horsfall glycoprotein (THG). Cells were either directly processed for analysis or cultured under normal cell culture conditions. Differentiation of primary isolates and cultured cells was assessed by reverse transcription polymerase chain reaction using characteristic markers. As controls, we used RNA from whole human kidney and cultured HK-2 cells. Additional characterizations were made by morphological analysis and western blotting. RESULTS: Primary isolated TALDC express the characteristic markers epidermal growth factor receptor, Na-K-2Cl transporter 2, epithelial calcium canal, and THG but were negative for Pax-2, aquaporin-2 and -3. Cultured TALDC were positive for epidermal growth factor receptor and Na-K-2Cl transporter 2 but have lost their epithelial calcium canal and THG expression and started to express Pax-2. All probes were positive for the specific markers kidney-specific cadherin and cytokeratin-8. Furthermore, differentiation of cultured TALDC was shown by cell morphology and their characteristic protein expression pattern. CONCLUSION: Our results highlight the purity of primary isolates and the differentiation of cultured TALDC, and show that they can be used as an in vitro system studies of the human thick ascending limb of Henle's loop and early distal tubule.
Assuntos
Túbulos Renais Distais/metabolismo , Alça do Néfron/metabolismo , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Anticorpos Monoclonais , Aquaporinas/genética , Aquaporinas/metabolismo , Western Blotting , Caderinas/genética , Caderinas/metabolismo , Diferenciação Celular , Forma Celular , Células Cultivadas , Receptores ErbB/genética , Receptores ErbB/metabolismo , Humanos , Separação Imunomagnética , Queratina-8/genética , Queratina-8/metabolismo , Túbulos Renais Distais/citologia , Túbulos Renais Distais/ultraestrutura , Alça do Néfron/citologia , Alça do Néfron/ultraestrutura , Mucoproteínas/genética , Mucoproteínas/imunologia , Mucoproteínas/metabolismo , Fator de Transcrição PAX2/genética , Fator de Transcrição PAX2/metabolismo , RNA Mensageiro/metabolismo , Simportadores de Cloreto de Sódio-Potássio/genética , Simportadores de Cloreto de Sódio-Potássio/metabolismo , Membro 1 da Família 12 de Carreador de Soluto , Canais de Cátion TRPV/genética , Canais de Cátion TRPV/metabolismo , Fatores de Tempo , UromodulinaRESUMO
BACKGROUND: Human urinary Tamm-Horsfall glycoprotein (THP) is a pleotropic protein that binds different cytokines and stimulates various immunocompetent cells. It is unclear whether these important functions of THP are altered in renal transplant patients. METHODS: We purified THPs from normal individuals (N-THP) and renal transplant patients receiving potent immunosuppressants (R-THP). The carbohydrate (CHO) compositions of THPs were probed by lectin-blotting and lectin-binding ELISA. The functions of THP were assessed by immune cell-stimulation as well as C1q, IL-1beta, IL-8 and TNF-alpha-binding assays. The roles of CHO moieties in THPs were analyzed using CHO-degrading enzyme digestion. RESULTS: Compared to that of N-THP, the binding capacity of R-THP to Maackia amurensis, Galanthus nivalis and Datura stamonium decreased, indicating that R-THP contained lesser amount of Siaalpha(2,3)Gal/GalNAc, mannose residues, and beta(1,4)GlcNAc, but not GlcNAc/branched mannose. The binding capacity of R-THP to complement C1q and tumor necrosis factor (TNF)-alpha was also decreased. The stimulating effect of R-THP on mononuclear cell (MNC) proliferation and polymorphonuclear neutrophil (PMN) phagocytosis was less potent than that of N-THP. We found that the defective MNC-stimulation by R-THP was due to impaired NF-kappaB p52 nuclear translocation. The cell-stimulating effects of N- and R-THP could be abolished by digesting them with CHO-degrading enzymes, beta-galactosidase and neuraminidase. Interestingly, a potent apoptosis-inducing effect of R-THP on MNC and PMN was noted. CONCLUSIONS: R-THP is not only modified in glycosylation but bears an apoptosis-inducing capacity on MNC and PMN, leading to an impaired immune function in renal transplant patients.
Assuntos
Transplante de Rim/imunologia , Mucoproteínas/metabolismo , Adulto , Idoso , Apoptose , Citocinas/metabolismo , Feminino , Glicosilação , Humanos , Lectinas/metabolismo , Leucócitos Mononucleares/citologia , Leucócitos Mononucleares/imunologia , Leucócitos Mononucleares/metabolismo , Masculino , Pessoa de Meia-Idade , Mucoproteínas/química , Mucoproteínas/imunologia , Neutrófilos/imunologia , Neutrófilos/metabolismo , Fagocitose , Proteínas Serina-Treonina Quinases/metabolismo , Uromodulina , Quinase Induzida por NF-kappaBRESUMO
AIMS: Tamm-Horsfall protein (THP) is urine's most abundant protein, but its biological function has remained elusive. Recently, THP-deficient (THP(-/-)) mice were shown to have difficulty clearing Escherichia coli from the urinary bladder. It has remained unclear if interaction between THP and E. coli is specific for E. coli or if THP has a versatile ability to clear a variety of bacteria from the bladder, and act as a broad host-defense mechanism against urinary tract infection (UTI). In this study, we examined the role of THP as a protective factor against UTI caused by bacteria other than E. coli, namely Klebsiella pneumoniae and Staphylococcus saprophyticus by determining if the THP(-/-) mouse has difficulty clearing these bacteria from its bladder. METHODS: THP gene knockout mice were generated by the technique of homologous recombination. K. pneumoniae and S. saprophyticus were introduced transurethrally, in separate experiments, into the bladders of the THP(-/-) and genetically similar wild-type (THP(+/+)) mice. Urine was collected at periodic intervals and cultured to quantitate the degree of bacteriuria. Bladders were surgically removed and examined histomorphometrically to determine the intensity of inflammation. RESULTS: Results showed that both with K. pneumoniae and with S. saprophyticus, the THP(-/-) mice had more severe bacteriuria in comparison with THP(+/+) mice. The inflammatory changes in the bladder were also markedly more intense in THP(-/-) mice with each of the bacterial species. CONCLUSIONS: These findings support the hypothesis that THP helps eliminate K. pneumoniae and S. saprophyticus from the urinary tract and acts as a general host-defense factor against UTI.
Assuntos
Adjuvantes Imunológicos , Cistite/microbiologia , Infecções por Klebsiella/microbiologia , Mucoproteínas/imunologia , Infecções Estafilocócicas/microbiologia , Bexiga Urinária/microbiologia , Animais , Antibacterianos/farmacologia , Bacteriúria/microbiologia , Bacteriúria/patologia , Cistite/patologia , Infecções por Klebsiella/patologia , Klebsiella pneumoniae , Camundongos , Camundongos Knockout , Infecções Estafilocócicas/patologia , Bexiga Urinária/patologia , UromodulinaRESUMO
Tamm-Horsfall protein (THP) is exclusively produced by renal tubular cells of the distal loop of Henle and is the most abundant urinary protein in mammals. The physiological function of THP has remained elusive for over half a century; however, new lines of research position it as a central antimicrobial molecule combating urinary tract infection (UTI). Furthermore, the genetic basis of familial juvenile hyperuricemic nephropathy (FJHN), glomerulocystic kidney disease (GCKD) and autosomal dominant medullary cystic kidney disease 2 (MCKD2) has been recently attributed to mutations within the THP gene. In these clinical conditions misfolded THP accumulates in the tubular cells, ultimately leading to overt renal insufficiency. UTI is the most common nonepidemic bacterial infection in humans, where both innate and adaptive components of the immune system as well as the bladder epithelium are involved in its prevention and clearance. Since the urogenital tract is devoid of typical physical barriers such as mucus or a ciliated epithelium, soluble mediators with potent anti-bacterial capabilities might exist. Recently, genetic ablation of the THP gene was shown to lead to severe infection and lethal pyelonephritis in experimental models of UTI. In addition, mounting evidence indicates that, beyond simply a direct antimicrobial activity, THP is a potent immunoregulatory molecule that induces specific THP-directed cell-mediated immunity. In light of these novel findings the particular role of THP as a specialized defense molecule in the urinary tract is discussed.